• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Kimberly Stegmaier, MD

Associate Professor, Department of Pediatrics, Harvard Medical School

Attending Physician, Pediatric Oncology, Boston Children's Hospital

Principal Investigator, Pediatric Oncology, Dana-Farber Cancer Institute

Contact Info

Kimberly Stegmaier
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 630D
Phone: 617-632-4438
Fax: 617-632-4850


Not Available.

DF/HCC Program Affiliation


Research Abstract

I conduct basic science research in the Department of Pediatric Oncology at the Dana-Farber Cancer Institute and the Broad Institute. My work focuses on new approaches to small molecule library screening with the goals of identifying candidate therapies for malignancies and new tool compounds for exploring pathways of oncogenesis. We developed a chemical genomic approach to screening, Gene Expression-based High-throughput Screening (GE-HTS), in which gene expression signatures serve as surrogates for different biological states. This method, using ligation-mediated multiplex amplification (LMA) with a fluorescent microsphere-based detection of marker genes, is a departure from traditional target-based or phenotype-based screening. It is entirely generic and can be applied to many different small molecule library screens. I am currently focusing my laboratory-based discovery efforts on two therapy platforms: 1) differentiation therapy and 2) modulation of "undruggable" oncoproteins.

In order to achieve the most ambitious objective, to bring confirmed chemicals to clinical trial, I will utilize the following core strategies: 1) prioritize libraries enriched for FDA-approved drugs and 2) prioritize libraries with chemicals with known mechanism of action. Such annotated libraries greatly facilitate the timely translation to clinical trial. For an already FDA-approved drug with a new potential clinical indication, I am equipped to perform preclinical in vitro testing and testing in mouse models with collaborators. For promising agents, I am dedicated to working with colleagues to bring them to trial.


View All Publications